Le Lézard
Classified in: Health
Subject: AVO

Guardians of opioid-dependent babies seek MDL class certification before Judge Polster


CLEVELAND, Jan. 7, 2020 /PRNewswire-PRWeb/ -- Attorneys representing America's most innocent victims in the nation's prescription opioid crisis took a significant step today within the Multi-District Litigation before Judge Daniel Polster in Cleveland, Ohio by seeking class certification of the guardians responsible for children injured by in-utero exposure to opioids and diagnosed with Neo-Natal Abstinence System or drug dependence.

States, cities, municipalities, hospitals and Native Americans have already gained such class certification status. Those classes do not include guardians of children who were born with Neo-Natal Abstinence Syndrome or drug dependent.

This would be the first-time children diagnosed with Neonatal Abstinence Syndrome, due to the opioid use of their birth mothers, would finally have redress of the lifelong physical and development disabilities and defects these children do and will experience, said Attorney Scott Bickford.

Mr. Bickford, who has argued on behalf of children with NAS for nearly two years before Judge Polster, said his team is being expanded by the legal expertise of Marc Dann, the former Attorney General of Ohio, and class-action experts Kelly and Tom Bilek.

"These children are the most vulnerable and blameless victims of the opioid crisis and will need lifelong medical monitoring and surveillance, as well as medical and social support services," said Mr. Dann.

"This generation of children is not yet lost but will be without substantial intervention. For two years, their needs have been subordinated to the less urgent needs of government entities which do not have the legal ability to bring claims for these children, do not owe the duty of care to them and will never guarantee their on-going needs are met. Nevertheless, the child's guardian will surely face and bear the fiduciary responsibility," Dann added.

The legal filing, with supporting evidence from leading medical experts in the areas of NAS and the scientific relationship between in-utero opioid exposure and birth defects, puts forth studies and testimony to support these arguments, making these main points:

Certification of a nationwide class of guardians of NAS children must occur in 2020, the attorneys argue in today's filing on behalf of families in 34 state class actions. This is underscored by the fact that nationwide, one of every five pregnant women on Medicaid has been prescribed opioids, the filing claims.

"In addition to medical monitoring claims to the guardian, plaintiffs seek to ensure that money needed to pay for testing and epidemiology is actually spent for the direct benefit of children born with NAS. More urgently, intervention and education of doctors and women of child-bearing age is required to immediately stop the possibility of more such births by educating them and the public that opioids cannot be used during pregnancy," said Mr. Dann.

The link to the filing and supportive statements is here.

 

SOURCE Opioid Justice Team


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: